STERIALS

The company is committed to researching, developing and commercializing breakthrough therapies for cancer, and is advancing multiple preclinical and clinical programs in the field of cancer with its partners. Abecma, a CAR-T cell therapy, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma who have received at least four prior lines of therapy. Delaware-born